Publication | Closed Access

Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy

Neuro-oncologyGliomaMedicinePathologyFibronectin AssemblyAnti-cancer AgentCancer BiologyCell BiologyTumor MicroenvironmentTumor BiologyExtracellular MatrixTransglutaminase 2